Key statistics dashboard for Fennec Pharmaceuticals Inc. (FENC). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical firm. Its leading investigational drug in clinical development is PEDMARK, a specialized formulation of sodium thiosulfate. This treatment is designed to shield young cancer patients from hearing damage (ototoxicity) that can be induced by platinum-based chemotherapy. The company, which was founded in 1996, previously operated under the name Adherex Technologies Inc.
Stock Data
| Price | $10.55 |
| Market Cap | $366M |
| Enterprise Value | $325.2M |
| Beta | 0.93 |
| Exchange | NASDAQ |
| Country | US |
Valuation Multiples
| P/E Ratio | -81.85 |
| Price / Book | 8.66 |
| P/S | 6.24 |
| EV/EBITDA | -136.88 |
| EV/Sales | 5.49 |
| EV/FCF | -159.42 |
| P/FCF | -181.18 |
| Earnings Yield | -0.89% |
| FCF Yield | -0.56% |
Profitability
| Gross Margin | 93.73% |
| EBIT Margin | -4.19% |
| EBITDA Margin | -4.01% |
| Operating Margin | -1.96% |
| Net Margin | -5.49% |
| Return on Equity | -11.71% |
| Return on Assets | -4.29% |
| Return on Invested Capital | -1.84% |
| Return on Capital Employed | -1.84% |
Financial Health
| Current Ratio | 5.85 |
| Quick Ratio | 5.66 |
| Cash Ratio | 3.33 |
| Debt / Equity | 0.00 |
| Debt / Assets | 0.00% |
| Net Debt / EBITDA | 17.36 |
| Interest Coverage | -1.29 |
| Piotroski F-Score | 1 |
| Altman Z-Score | 0.49 |
Per-Share Data
| Revenue per share | 1.71 |
| Book Value per share | 1.23 |
| Cash per share | 1.19 |
| FCF per share | -0.06 |
| Tangible Book Value per share | 1.23 |
| Dividend per share | 0.00 |
Analyst Consensus
| Strong Buy | 0 |
| Buy | 7 |
| Hold | 0 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 7 |
| Avg rating (1-5) | 1.00 |
Related companies: AARD · AVTX · BDTX · CRBU · ENTA · EPRX · NAUT
Explore sector: Healthcare · Biotechnology
More sections of FENC: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks